CCL18MVD在乳腺癌组织中表达及其与患者预后关系研究.doc

CCL18MVD在乳腺癌组织中表达及其与患者预后关系研究 　　[摘要] 目的 研究趋化因子配体18（CCL18）与肿瘤微血管密度（MVD）在乳腺癌组织中表达水平及与患者预后的关系。 方法 收集2011年7月～2012年12月我院乳腺外科病理确诊为乳腺癌患者癌组织标本90例，癌旁组织标本30例及乳腺良性病变组织30例。应用免疫组化法检测CCL18和MVD在3类组织中表达水平。结果 CCL18 在乳腺癌组织组的表达明显高于癌旁组织组和良性组织组（P=0.000），并且乳腺癌的分期越晚CCL18在乳腺癌组织组表达水平越高（P=0.000），乳腺癌组织组MVD的表达明显高于其余两组（P=0.000），且表达水平在Ⅲ期乳腺癌组织中明显高于I期和Ⅱ期（P=0.000）。 结论 CCL18和MVD均可作为乳腺癌标志物之一，两者表达水平对于治疗和预后均有重要的意义。 　　[关键词] 乳腺癌；趋化因子18；肿瘤微血管密度；预后 　　[中图分类号] R737.9 [文献标识码] B [文章编号] 1673-9701（2013）36-0020-03 　　The expression of CCL18 and MVD in breast cancer and the relationship between their expression levels and patients’ prognosis 　　HU Zujian1 XU Haibin1 REN Xingchang2 HE Junling1 SU Kunlun1 YANG Ouou1 LUO Hua1 LIU Dianlei3 　　1. Department of Breast Oncology， Hospital of Traditional Chinese Medicine of Hangzhou City in Zhejiang Province，Hangzhou 310007，China；2.Department of Pathology， Hospital of Traditional Chinese Medicine of Hangzhou City in Zhejiang Province，Hangzhou 310007，China；3.Department of General Surgery， Hospital of Traditional Chinese Medicine of Hangzhou City in Zhejiang Province，Hangzhou 310007，China 　　[Abstract] Objective To investigate the expression of CCL18 （chemokine CC-motif ligand 18） and MVD （microvessel density） in breast cancer and the relationship between their expression levels and patients’ prognosis. Methods Ninety cancer tissue samples and 30 pericarcinoma tissue samples from patients with breast cancer， and 30 tissue samples from benign breast diseases diagnosed in the department of pathology in our hospital were collected from July 2011 to December 2012. Immunochemistry was used to detect the expression levels of CCL18 and MVD in the tissue samples. Results The expression of CCL18 was significantly higher in cancer tissue samples than those in pericarcinoma tissue samples and samples from benign breast diseases（P=0.000）， and the expression level of CCL18 was much higher in advanced breast cancer （P=0.000）. The expression of MVD was significantly higher in cancer tis